[DOI] [PubMed] [Google Scholar] 129
They show an average weight loss of 17% after 64 weeks , with early responders in trials losing up to 22%
Tirzepatide is a dual GIP and GLP-1 receptor agonist licensed for type 2 diabetes treatment in the UK Lymphadenopathy is not listed in the Summary of Product Characteristics or reported in SURPASS or SURMOUNT clinical trials Common Mounjaro side effects are predominantly gastrointestinal, including nausea, vomiting, diarrhoea, and reduced appetite Lymph node swelling during treatment may result from infections, vaccinations, local inflammation, or other unrelated conditions Persistent, enlarging, or hard lymph nodes require GP evaluation to exclude serious underlying causes including malignancy Report any suspected adverse effects through the MHRA Yellow Card Scheme for ongoing pharmacovigilance monitoring Table of Contents Understanding Mounjaro and Its Common Side Effects Mounjaro (tirzepatide) is a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus
Melynda Barnes, Ro's chief medical officer.
every 20 to 23 days Every 2 months: refill is processed approx
Some describe waiting up to a month for their medication to arrive
